ORYX’ development strategy bridges the gap between academic research and the pharmaceutical industry for new cancer therapies. Today, the company is developing three clinical cancer immunotherapy projects in indications with high unmet medical need. ORYX is the exclusive licensee of premier cancer immunotherapy substances from the German Cancer Research Center (DKFZ) and the University of Heidelberg. The Company has established close collaborations with DKFZ, Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Nordwest Hospital Frankfurt, Darmstadt Clinic and leading experts as well as an outstanding network of scientific and clinical advisors.
taking innovation from lab to patient
Oncolytic viruses infect and lyse tumor cells and evoke a strong anti-tumor immune response. ORYX develops the oncolytic parvovirus H1 (H-1PV) which is a wild type rat virus with effects in a broad range of human tumors. Clinical development began in 2011 and continues to show promising results in terms of safety, efficacy and immune response.
Therapeutic vaccines treat cancers by enhancing a patient’s natural defenses against the tumor. ORYX on the one hand focusses on the human cyclin-dependent kinase inhibitor p16, a tumor antigen expressed in various cancers. On the other hand, ORYX focusses on MSI, which targets cancers that arise from the lack of DNA mismatch repair.
Meet us at:
BIO-Europe Spring, Vienna, Austria, March 25-27, 2019
For more information on upcoming conferences, please click here